Other Lupus News

September 17, 2014

The last 21st Century Cures roundtable held in Washington last week discussed opportunities to accelerate the discovery, development, and delivery of new cures and treatments. NIH Director Dr. Francis Collins talked about the Accelerating Medicine Partnership which is working toward cures for lupus and other chronic diseases.

September 9, 2014

Yale Cancer Center researchers recently published findings showing a possible way to use lupus antibodies to “sabotage” certain cancer cells. The study found that those cancer cells unable to repair damage to their own DNA were “significantly more vulnerable to attack by lupus antibodies.”

July 2, 2014

Animal research shows that an investigational drug that blocks the enzyme Cdk5 might help reduce the injury that can result following a stroke, a potential complication of lupus.

June 30, 2014

The FDA has granted Breakthrough Therapy Designation to idarucizumab, a potential antidote for the anticoagulant Pradaxa. Many lupus patients receive anticoagulation; new oral anticoagulants like Pradaxa are effective but can be dangerous because their anticoagulant event cannot be reversed if patients start to bleed.

May 21, 2014

It’s International Clinical Trials Day. Watch the new AllTrials campaign video. And change something.  

May 15, 2014

MedPage Today writer Nancy Walsh reports on a U.K. study showing that patients with lupus and other autoimmune diseases as well as certain other chronic conditions are at increased risk for shingles. While higher among older patients, the risk for shingles is still higher among younger people with lupus.

May 13, 2014

Task force agrees vitamin K antagonists like warfarin remain the mainstay of anticoagulation for antiphospholipid syndrome and says rituximab and hydroxychloroquine can be useful in some cases.

May 13, 2014

Rheumatology Network reports: An international task force of multi-speciality experts says the "treat-to-target" approach can be applied just as effectively in systemic lupus erythematosus (SLE) as it has proven in rheumatoid arthritis.

Pages